X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/02/08/2825783/0/en/Genenta-Demonstrated-Reprogramming-of-the-Tumor-Microenvironment-in-GBM-Patients-Paving-the-Way-for-Innovative-Treatments-of-Solid-Tumors.html
https://www.globenewswire.com//news-release/2023/09/06/2738191/0/en/Genenta-to-Present-at-Upcoming-Scientific-and-Investor-Conferences.html
https://www.globenewswire.com/news-release/2023/07/28/2712899/0/en/Genenta-Announces-Ongoing-Clinical-Trial-Progress-and-Proposed-Expansion-in-Solid-Tumor-Treatments.html
https://www.onclive.com/view/european-commission-grants-orphan-drug-designation-to-temferon-for-glioma
https://www.globenewswire.com/news-release/2023/05/16/2669815/0/en/Genenta-to-Provide-Update-on-Lead-Product-Temferon.html
https://www.globenewswire.com/news-release/2023/04/03/2639396/0/en/Genenta-Announces-Extension-of-License-Agreement-with-Ospedale-San-Raffaele-to-All-Solid-Tumor-Indications.html
https://www.globenewswire.com/news-release/2023/03/02/2619075/0/en/FDA-Grants-Orphan-Drug-Designation-to-Temferon-for-Treatment-of-Glioblastoma-Multiforme.html
https://www.globenewswire.com/news-release/2023/02/07/2602794/0/en/Genenta-Science-and-AGC-Biologics-Enter-Development-and-Manufacturing-Service-Agreement.html
https://www.globenewswire.com/news-release/2022/11/07/2549684/0/en/Genenta-Update-at-SITC22-Indicates-Potential-for-Anti-Tumor-Immune-System-Reset-after-Temferon-Treatment-in-Glioblastoma-Patients.html
https://www.globenewswire.com/news-release/2022/10/24/2539850/0/en/Genenta-Provides-First-Half-2022-Business-Update-and-Financial-Results.html
Market Place
Share 
